Memphis, TNNCT07531095Now EnrollingIRB Ready

Small Cell Lung Cancer Clinical Trial in Memphis, TN

Access cutting-edge small cell lung cancer treatment through this clinical trial at a research site in Memphis. Study-provided care at no cost to qualified participants.

Sponsored by Amgen

Quick Self-Assessment

See if you qualify for this Memphis location

Preparing your pre-screening questions…

Expert Care in Memphis

Access small cell lung cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related small cell lung cancer treatment provided free

Apply for This Memphis Location

Check if you qualify for this small cell lung cancer clinical trial in Memphis, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Memphis

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Memphis site if eligible
  4. 4Begin participation

About This Small Cell Lung Cancer Study in Memphis

The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.

Sponsor: Amgen

Who Can Participate

Inclusion Criteria

Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
Participants with Histologically or cytologically confirmed SCLC:
For Part 1, participants must have SCLC that has progressed or recurred following at least 1 line of platinum-based anti-cancer therapy.
For Parts 1 and 2, participants must have progressed or recurred following at least 1 line of platinum-based therapy. No prior tarlatamab is allowed in Cohort 2-1.
For Part 3, participants must have extensive-stage SCLC (ES-SCLC) with no prior systemic treatment other than 1 cycle of platinum-based chemotherapy. Note: Participants with prior treatment for limited-stage SCLC (LS-SCLC) before diagnosis of ES SCLC are permitted.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
At least 1 measurable lesion as defined per RECIST v1.1 within 21-day screening period, not previously irradiated.
Adequate organ function (hematological, coagulation, renal, hepatic, pulmonary, and cardiac function).

Exclusion Criteria

Symptomatic CNS metastases. Participants with treated brain metastases are eligible provided they meet the criteria specified in the protocol.
History of interstitial lung disease (ILD)/pneumonitis.
Received thoracic radiation therapy within 90 days prior to first dose of trial intervention.
Prior therapy with any delta-like ligand 3 (DLL3)-directed therapy.
Prior exposure to topoisomerase I inhibitors or antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload.
Receiving strong CYP3A4 or CPY2D6 inhibitors within 14 days or 5 half-lives (whichever is longer) before the first dose of trial treatment.
Enrollment in any tarlatamab clinical trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Memphis?

Yes, this clinical trial (NCT07531095) has an active research site in Memphis, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Small Cell Lung Cancer Treatment Options in Memphis, TN

If you're searching for small cell lung cancer treatment options in Memphis, TN, this clinical trial (NCT07531095) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Memphis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all small cell lung cancer clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Memphis, TN

See all lung cancer clinical trials recruiting in Memphis — not just this study.

Browse Lung Cancer Trials in Memphis →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSmall Cell Lung Cancer TrialsNon-Small Cell Lung Cancer TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Memphis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Memphis, TN